

FIG. 1A




n=number of patients
p value derived by Student's t-test

FIG. 1B



*anti-fXa=0.05-0.75 U/ml
** anti-fXa=0.07-1.04 U/ml

FIG. 1C



*anti-fXa=BLQ-0.23 U/ml
**anti-fXa=BLQ-0.49 U/ml

FIG. 2




FIG. 3



40000
30000
20000
10000
0
RFU
0
250
500
750
1000
Time (sec)
1000
500
250
125
62.5
31.75
15.25
0

FIG. 4A



40000
30000
20000
10000
0
RFU
0
250
500
750
1000
Time (sec)
4000
2000
1000
500
250
125
62.5
0

FIG. 4B



40000
30000
20000
10000
0
RFU
0
250
500
750
1000
Time(sec)
250
125
0

FIG. 5



125
100
75
50
25
0
-25
% Inhibition of Thrombin Generation
0
50
100
150
200
250
Betrixaban (ng/ml)

FIG. 6



40.0
20.0
0.0
VTE (%)
20.0
15.4
10.0
15.9
16.0
Betrixaban 15mg
Betrixaban 40mg
Enox A
Enox B
Enox C

FIG. 7



Reduction from baseline thrombin generation (RFU)
100000
80000
60000
40000
20000
0
Betrixaban 15mg
Betrixaban 40mg
Enoxaparin
Baseline
Day 2
Discharge
Venogram

FIG. 8




Anti-Xa Activity (U/mL)
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
Betrixaban 15 mg
Betrixaban 40 mg
Enoxaparin
Baseline
Day 2
Discharge
Venogram

FIG. 9


Betrixaban Concentration
25
20
15
10
5
0
Betrixaban 15mg
Betrixaban 40mg
Day 2
Discharge
Venogram